全文获取类型
收费全文 | 7839篇 |
免费 | 627篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 263篇 |
妇产科学 | 275篇 |
基础医学 | 1081篇 |
口腔科学 | 117篇 |
临床医学 | 923篇 |
内科学 | 1374篇 |
皮肤病学 | 132篇 |
神经病学 | 754篇 |
特种医学 | 201篇 |
外科学 | 846篇 |
综合类 | 71篇 |
一般理论 | 10篇 |
预防医学 | 895篇 |
眼科学 | 158篇 |
药学 | 548篇 |
中国医学 | 33篇 |
肿瘤学 | 701篇 |
出版年
2023年 | 58篇 |
2022年 | 93篇 |
2021年 | 206篇 |
2020年 | 163篇 |
2019年 | 196篇 |
2018年 | 188篇 |
2017年 | 147篇 |
2016年 | 195篇 |
2015年 | 192篇 |
2014年 | 301篇 |
2013年 | 382篇 |
2012年 | 600篇 |
2011年 | 570篇 |
2010年 | 335篇 |
2009年 | 328篇 |
2008年 | 529篇 |
2007年 | 506篇 |
2006年 | 484篇 |
2005年 | 449篇 |
2004年 | 463篇 |
2003年 | 460篇 |
2002年 | 397篇 |
2001年 | 72篇 |
2000年 | 36篇 |
1999年 | 72篇 |
1998年 | 92篇 |
1997年 | 83篇 |
1996年 | 53篇 |
1995年 | 66篇 |
1994年 | 61篇 |
1993年 | 55篇 |
1992年 | 46篇 |
1991年 | 46篇 |
1990年 | 44篇 |
1989年 | 34篇 |
1988年 | 27篇 |
1987年 | 32篇 |
1986年 | 30篇 |
1985年 | 30篇 |
1984年 | 36篇 |
1983年 | 22篇 |
1982年 | 27篇 |
1981年 | 25篇 |
1978年 | 20篇 |
1977年 | 20篇 |
1976年 | 15篇 |
1975年 | 20篇 |
1973年 | 24篇 |
1972年 | 25篇 |
1971年 | 15篇 |
排序方式: 共有8497条查询结果,搜索用时 15 毫秒
101.
Dina Chelouche Lev Amir Onn Vladislava O Melinkova Claudia Miller Valerie Stone Maribelis Ruiz Eric C McGary Honnavara N Ananthaswamy Janet E Price Menashe Bar-Eli 《Journal of clinical oncology》2004,22(11):2092-2100
PURPOSE: In recent years, the incidence of cutaneous melanoma has increased more than that of any other cancer. Dacarbazine is considered the gold standard for treatment, having a response rate of 15% to 20%, but most responses are not sustained. Previously, we have shown that short exposure of primary cutaneous melanoma cells to dacarbazine resulted in the upregulation of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF). The purpose of the present study was to determine how long-term exposure of melanoma cells to dacarbazine would affect their tumorigenic and metastatic potential in vivo. MATERIALS AND METHODS: The primary cutaneous melanoma cell lines SB2 and MeWo were repeatedly exposed in vitro to increasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D and MeWo-D were selected and examined for their ability to grow and metastasize in nude mice. RESULTS: The dacarbazine-resistant cell lines SB2-D and MeWo-D exhibited increased tumor growth and metastatic behavior in vivo. This increase could be explained by the activation of RAF, MEK, and ERK, which led to the upregulation of IL-8 and VEGF. More IL-8, VEGF, matrix metalloproteinase-2 (MMP-2), and microvessel density (CD-31) were found in tumors produced by SB2-D and MeWo-D in vivo than in those produced by their parental counterparts. No mutations were observed in BRAF. CONCLUSION: Our results have significant clinical implications. Treatment of melanoma patients with dacarbazine could select for a more aggressive melanoma phenotype. We propose that combination treatment with anti-VEGF/IL-8 or MEK inhibitors may potentiate the therapeutic effects of dacarbazine. 相似文献
102.
Lee M Krug Christopher G Azzoli Mark G Kris Vincent A Miller Nushmia Z Khokhar William Tong Michelle S Ginsberg Ennapadam Venkatraman Leslie Tyson Barbara Pizzo Valerie Baez Kenneth K Ng F M Sirotnak 《Clinical cancer research》2003,9(6):2072-2078
PURPOSE: 10-propargyl-10-deazaaminopterin (PDX) has superior antitumor efficacy in mouse xenograft models, likely attributable to increased uptake by the RFC-1 folate transporter and greater intracellular polyglutamylation. In a previous Phase I trial, stomatitis was the dose-limiting (and only clinically significant) toxicity of PDX. The recommended Phase II dose was 150 mg/m(2) i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial. EXPERIMENTAL DESIGN: Patients had stage IIIB or IV NSCLC and either no previous chemotherapy or progression after initial response or stable disease to one previous chemotherapy regimen. Initially, PDX was administered at a dose of 150 mg/m(2) every 2 weeks. However, to decrease the frequency of stomatitis, the last 10 patients were treated at a dose of 135 mg/m(2). We planned to correlate PDX effects with folate and homocysteine levels and the expression of genes associated with folate transport and polyglutamylation. RESULTS: Thirty-nine patients were enrolled, 38 of whom were evaluable for response. Four patients had confirmed, major objective responses (10% based on intent to treat, 95% confidence interval 3-25) lasting 4, 9, 12, and 15 months. Twelve patients (31%) had stable disease. The median survival was 13.5 months. The predicted 1- and 2-year survival rates were 56 and 36%, respectively. Two patients (5%) suffered grade 4 stomatitis, and 6 (15%) had grade 3. No clinically significant myelosuppression occurred. No correlation between homocysteine or serum folate levels and severity of stomatitis was observed. Area under the curve (calculated using a limited sampling model) correlated with mucositis grade. A trend was noted between folate transporter expression and treatment effect. CONCLUSIONS: The broad applicability of this new antifolate with limited toxicity and proven efficacy in NSCLC encourage further development of this compound. Several trials are now underway combining PDX with other chemotherapeutic agents and testing its efficacy in other cancers. 相似文献
103.
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. 总被引:7,自引:0,他引:7
Peter B Illei Valerie W Rusch Maureen F Zakowski Marc Ladanyi 《Clinical cancer research》2003,9(6):2108-2113
PURPOSE: Homozygous deletions at chromosome region 9p21 targeting the CDKN2A gene have been reported as a common cytogenetic abnormality in mesothelioma. MTAP, a gene approximately 100-kb telomeric to CDKN2A, encodes methylthioadenosine phosphorylase, an enzyme essential in the salvage of cellular adenine and methionine, and its codeletion with CDKN2A has been reported in other tumors. The aim of this study was to define the prevalence of homozygous deletion of CDKN2A alone or in combination with MTAP in a large series of pleural mesothelioma. EXPERIMENTAL DESIGN: We used a fluorescent in situ hybridization assay for CDKN2A and MTAP on interphase nuclei in imprints of frozen tissue from 95 cases of pleural mesothelioma. Histologically, the cases were classified as epithelial (71), biphasic (19) and sarcomatous (5). In each experiment, a 9p21 locus specific probe and a chromosome 9 centromeric probe were used and fluorescent in situ hybridization signals for both probes were simultaneously recorded in at least 100 nuclei. Cases were considered homozygously deleted if both 9p21 signals were lost in at least 20% of nuclei. RESULTS: Overall, 70 cases (74%) had homozygous deletion of CDKN2A. MTAP was codeleted in 64 of these cases (91%). No case with MTAP deletion without CDKN2A deletion was identified. Homozygous loss of CDKN2A was seen in 49 of 71 epithelial (70%), 16 of 19 biphasic (89%), and 5 of 5 sarcomatous (100%) mesotheliomas. CONCLUSIONS: Homozygous deletion of CDKN2A is seen in the majority of pleural mesotheliomas, and MTAP is codeleted in most of these cases. Previous cell line studies have shown that loss of MTAP renders cells dependent on de novo synthesis of purine derivatives. Thus, the particularly high prevalence of MTAP codeletion in mesothelioma makes it an ideal candidate for trials of targeted therapy using inhibitors of de novo AMP synthesis (e.g., L-alanosine). 相似文献
104.
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. 总被引:13,自引:0,他引:13
Robert J Downey Tim Akhurst David Ilson Robert Ginsberg Manjit S Bains Mithat Gonen Heng Koong Marc Gollub Bruce D Minsky Maureen Zakowski Alan Turnbull Steven M Larson Valerie Rusch 《Journal of clinical oncology》2003,21(3):428-432
PURPOSE: Whole-body 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging before and after induction therapy was prospectively evaluated in patients with esophageal cancer to determine whether changes in PET images could measure response to therapy. PATIENTS AND METHODS: Between April 1997 and April 1999, 39 patients (34 men and five women; median age, 59 years; range, 36 to 76 years) with esophageal cancer were prospectively enrolled in a single-institution clinical trial of staging, including PET, induction therapy, restaging including PET, and esophagectomy. All patients undergoing esophagectomy after induction therapy (n = 17) were followed either to recurrence, to death, or through a disease-free interval of at least 24 months. RESULTS: PET after standard staging studies and before therapy imaged undetected sites of metastatic disease in six patients (15%). Restaging (including PET) after induction therapy did not identify any patients with disease progression or any patients with loco-regionally unresectable disease at exploration. The median decrease in the standardized uptake value (SUV) during induction therapy was 59%. After R0 esophagectomy, the 2-year disease-free and overall survival was 38% and 63%, respectively, among patients who had a less than 60% decrease in SUV, and 67% and 89%, respectively, among patients who had a greater than 60% decrease in SUV (P =.055 and P =.088, respectively). CONCLUSION: Compared with conventional imaging, PET detects additional sites of metastatic disease at initial evaluation. After induction therapy, PET did not add to the estimation of loco-regional resectability and did not detect new distant metastases. However, changes in [18F]FDG PET may predict disease-free and overall survival after induction therapy and resection in patients with esophageal cancer. Further evaluation in larger trials is warranted. 相似文献
105.
106.
Background
Environmental exposure to lead remains a significant health problem for children. The costs of lead exposure in children are estimated to be considerably more than other childhood diseases of environmental origin. While long-term trends in blood lead levels (BLLs) among children are declining, seasonal variation persists. Cross-sectional studies have found a peak in summer months. Part of this variation may be due to increased exposure to lead paint on window sills and through increased contact with soils containing lead during the summer. The current study represents the largest published population-based study on seasonality and trends in the BLLs of children to date. In addition, the results offer a comparison of recent data on seasonality of BLLs in New York State children, to studies conducted over the past three decades. 相似文献107.
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 总被引:1,自引:0,他引:1
Emanuel F Petricoin Verena E Bichsel Valerie S Calvert Virginia Espina Mary Winters Lynn Young Claudio Belluco Bruce J Trock Marc Lippman David A Fishman Dennis C Sgroi Peter J Munson Laura J Esserman Lance A Liotta 《Journal of clinical oncology》2005,23(15):3614-3621
Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network of intracellular and extracellular signaling cascades. These protein signaling circuits are the ultimate targets of molecular therapy. Each patient's tumor may be driven by a distinct series of molecular pathogenic defects. Thus, for any single molecular targeted therapy, only a subset of cancer patients may respond. Individualization of therapy, which tailors a therapeutic regimen to a tumor molecular portrait, may be the solution to this dilemma. Until recently, the field lacked the technology for molecular profiling at the genomic and proteomic level. Emerging proteomic technology, used concomitantly with genomic analysis, promises to meet this need and bring to reality the clinical adoption of molecular stratification. The activation state of kinase-driven signal networks contains important information relative to cancer pathogenesis and therapeutic target selection. Proteomic technology offers a means to quantify the state of kinase pathways, and provides post-translational phosphorylation data not obtainable by gene arrays. Case studies using clinical research specimens are provided to show the feasibility of generating the critical information needed to individualize therapy. Such technology can reveal potential new pathway interconnections, including differences between primary and metastatic lesions. We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material. 相似文献
108.
Abeer M Shaaban Valerie Speirs 《Clinical cancer research》2005,11(22):8222; author reply 8222-8222; author reply 8223
109.
110.
Emily Banks Gillian Reeves Valerie Beral Diana Bull Barbara Crossley Moya Simmonds Elizabeth Hilton Stephen Bailey Nigel Barrett Peter Briers Ruth English Alan Jackson Elizabeth Kutt Janet Lavelle Linda Rockall Matthew G Wallis Mary Wilson Julietta Patnick 《British medical journal》2004,328(7451):1291-1292